ROCHE AND AMORCHEM ANNOUNCE ALLIANCE FOCUSED ON MYOTONIC MUSCULAR DYSTROPHY 1

摘要

Roche and Montreal-based venture capital firm AmorChem L.R have entered into a collaboration to discover novel small molecule disease-modifying therapies for the treatment of myotonic muscular dystrophy 1, or Steinert's disease. Myotonic dystrophy is a progressive degenerative disease that affects an estimated 130,000 people in US. EU and Japan. There is currently no approved treatment available to slow or stop disease progression.